Skip to main content

Free Content Rapid onset of seizure suppression with pregabalin adjunctive treatment in patients with partial seizures

Download Article:

You have access to the full text article on a website external to Ingenta Connect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library

Summary Purpose: 

To determine the time at which pregabalin demonstrates seizure-suppressing activity when given as adjunctive treatment to patients with refractory partial seizures. Methods: 

Data from four similar 12-week, randomized, double-blind, placebo-controlled, parallel-group trials in patients with refractory partial seizures were pooled to provide an adequate sample to compare the proportion of patients free of seizures on each study day between pregabalin (combined 150–600 mg/day groups) and placebo (combined groups). A generalized estimating equation (GEE) statistical model was used to perform pairwise comparisons on each study day. In several pregabalin dosage groups the dosage was escalated during days 1–7, whereas in others pregabalin was initiated at a fixed dosage without escalation. Results: 

The proportion of patients free of seizures on any treatment day was greater in the combined pregabalin groups compared with baseline. Differences were not observed between the placebo group and baseline. A significantly greater proportion of patients were free of seizures in the combined pregabalin 150–600 mg/day and the pregabalin 600 mg/day fixed-dosage groups compared with the placebo groups from treatment day 2 onward (p < 0.05). From day 8 (coinciding with completion of the 1-week dosage-escalation period in two studies) onward, the proportion of patients free of seizures per day in the pregabalin groups remained relatively constant. Discussion: 

This exploratory analysis of a refractory population using a rigorous endpoint demonstrates that pregabalin rapidly reduced the frequency of partial seizures. At the dosing schemes most commonly used in placebo-controlled trials, significant seizure-suppressing activity was observed after only 2 days of treatment.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Anticonvulsant; Efficacy; Epilepsy; Partial seizures; Pregabalin; Rapid onset

Document Type: Research Article

Affiliations: 1: Department of Neurology, University of Miami School of Medicine, Miami Veterans Affairs Medical Center, Miami, Florida, U.S.A. 2: Clinical Pharmacology Unit, University of Pavia and Institute of Neurology IRCCS C. Mondino Foundation, Pavia, Italy 3: Pfizer Global Research and Development, Pfizer Inc., Ann Arbor, Michigan, U.S.A. 4: Pfizer Global Pharmaceuticals, Pfizer Inc., New York, New York, U.S.A.

Publication date: 2009-08-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more